5 Health Tips to Stay Fit
- 1 Apple / Day - No Doctor
- 1 Tulsi Leaf / Day - No Cancer
- 1 Lemon / Day - No Fat
- 1 Cup Milk / Day - No Bone Problems
- 3 Ltrs Water / Day - No Diseases
New inhibitor drug shows promise in relapsed leukemia
A new drug shows promise in its ability to target one of the most common and sinister mutations of acute myeloid leukemia (AML), according to researchers at the Perelman School of Medicine at the University of Pennsylvania and Penn's Abramson Cancer Center. The Fms-like tyrosine kinase 3 (FLT3) gene mutation is a known predictor of AML relapse and is associated with short survival. In a first-in-human study, researchers treated relapsed patients with gilteritinib, an FLT3 inhibitor, and found it was a well-tolerated drug that led to frequent and more-sustained-than-expected clinical responses, almost exclusively in patients with this mutation. They published their findings today in The Lancet Oncology. FLT3 is one of the most commonly mutated genes in AML patients. FLT3 mutations are found in about 30 percent of patients' leukemia cells. Clinically, these mutations are associated with aggressive disease that often leads to rapid relapse, after which the overall survival is a...
Comments
Post a Comment